Related Experiment Video

Updated: Jun 27, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

Effectiveness of Faster Aspart versus Insulin Aspart in Children with Type 1 Diabetes: A Meta-Analysis

Jie Wei1, Yueer Wang2

  • 1Department of Pediatrics, The First People's Hospital of Huzhou, First Affiliated Hospital of Huzhou Normal University, Huzhou 313000, Zhejiang Province, China.

Iranian Journal of Public Health
|May 2, 2024
PubMed

Insights

Faster-acting insulin aspart (faster aspart) significantly reduces HbA1c levels in children with type 1 diabetes compared to standard insulin aspart (IAsp). This new formulation offers improved blood sugar control for pediatric patients with type 1 diabetes.

Area of Science:

  • Pediatric Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Intensive insulin regimens are crucial for managing type 1 diabetes in children and adolescents.
  • Fast-acting insulin aspart (faster aspart) is a novel insulin formulation designed for enhanced stability and rapid absorption.
  • This study addresses the need for effective glycemic control strategies in pediatric type 1 diabetes.

Purpose of the Study:

  • To compare the efficacy of faster aspart versus standard insulin aspart (IAsp) in improving glycemic control in children with type 1 diabetes.
  • To evaluate the impact of faster aspart on HbA1c levels and BMI in pediatric patients.
  • To synthesize evidence from randomized-controlled trials on faster aspart's performance in a pediatric population.

Main Methods:

  • A systematic meta-analysis of randomized-controlled trials was conducted.
  • Searches were performed across major databases (PubMed, MEDLINE, Embase, Cochrane, Web of Science, Google Scholar) from 2000 to 2023.
  • Heterogeneity was assessed using Cochrane Q statistics, and a random-effect model was employed for data synthesis.

Main Results:

  • Faster aspart demonstrated a significant reduction in HbA1c levels compared to IAsp (mean difference: 5.44 [0.45, 10.44] and 7.71 [7.16, 8.26]).
  • No significant difference in Body Mass Index (BMI) was observed between the two insulin formulations (mean difference: -0.06 [-0.60, 0.48]).
  • Faster aspart exhibited a quicker onset and earlier exposure profile.

Conclusions:

  • Faster-acting insulin aspart may offer superior glycemic control in children and adolescents with type 1 diabetes compared to standard insulin aspart.
  • The enhanced pharmacokinetic profile of faster aspart, including faster onset and absorption, potentially contributes to better blood glucose management.
  • Further consideration of faster aspart is warranted for optimizing diabetes care in pediatric populations.
Abstract

Keywords:
Care modelDiabetes type 1Faster aspartIAspInsulin aspart

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.1K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.8K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
168
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
191
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192